EcoDrugPlus

Solute Carrier Family 6 Member 3

Ensembl ID : ENSBSLG00000017958
Gene Symbol: SLC6A3
3 Cross references
167 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSBSLG00000012810
Gene Symbol: SLC6A4
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSBSLG00000006886
Gene Symbol: SLC6A9
3 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSBSLG00000002899
Gene Symbol: SLC9A3
3 Cross references
237 Possible Orthologues:

Somatostatin Receptor Type 2-Like

Ensembl ID : ENSBSLG00000023495
Gene Symbol: LOC114845380
2 Cross references
192 Possible Orthologues:

Somatostatin Receptor Type 2-Like

Ensembl ID : ENSBSLG00000019211
Gene Symbol: LOC114860060
2 Cross references
192 Possible Orthologues:

Somatostatin Receptor Type 5-Like

Ensembl ID : ENSBSLG00000001570
Gene Symbol: LOC114862321
2 Cross references
184 Possible Orthologues:

Sphingosine Kinase 2-Like

Ensembl ID : ENSBSLG00000019768
Gene Symbol: LOC114842665
2 Cross references
202 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSBSLG00000010921
Gene Symbol: S1PR1
3 Cross references
193 Possible Orthologues:

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSBSLG00000003159
Gene Symbol: SYK
3 Cross references
202 Possible Orthologues:

Steroid 17-Alpha-Hydroxylase/17,20 Lyase

Ensembl ID : ENSBSLG00000018948
Gene Symbol: LOC114841926
3 Cross references
211 Possible Orthologues:

Steroid 5 Alpha-Reductase 2

Ensembl ID : ENSBSLG00000008888
Gene Symbol: SRD5A2
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).